fig7

Figure 7. Effect of secretomes on inflamed chondrocytes. (A) Gene expression modulation (2^-ΔCt) for chondrocytes exposed to IL-1β without and with secretomes at 1:1 dilution (^*P ≤ 0.05, ^**P ≤ 0.01, ^***P ≤ 0.001, ^****P ≤ 0.0001; N = 3). After assessment of normality of data distribution by the Shapiro-Wilk test, statistical significance was determined using one-way ANOVA; (B) Principal component analysis for 2^-ΔCt values of tested genes showing reversion of secretome-treated inflamed-chondrocytes signature towards healthy control samples. Data presented in PowerPoint. ASC: Adipose-derived mesenchymal stromal cell; BMSC: bone marrow-derived mesenchymal stromal cell; hAMSC: human amniotic mesenchymal stromal cell; CTRL: control; IL: interleukin; IL-1β: interleukin 1 beta; CCL5: C-C motif chemokine ligand 5; CTSS: cathepsin S; IDO1: indoleamine 2,3-dioxygenase 1; PCA: principal component analysis; PC1: principal component 1; PC2: principal component 2; ΔCt: delta cycle threshold; ANOVA: analysis of variance.